TriSalus Life Sciences (TLSI) Total Debt (2023 - 2026)

TriSalus Life Sciences' Total Debt history runs 4 years deep, the most recent figure standing at $33.1 million for Q1 2026.

• On a quarterly basis, Total Debt rose 4.35% year-over-year to $33.1 million in Q1 2026; TTM through Mar 2026 was $33.1 million, a 4.35% increase from a year earlier, with the FY2025 full-year figure at $33.0 million, up 49.64% from the prior year.
• Total Debt was little changed at $33.1 million in Q1 2026 per TLSI's latest filing, from $33.0 million in the prior quarter.
• Across five years, Total Debt topped out at $33.1 million in Q1 2026 and bottomed at $629222.0 in Q2 2023.
• The 4-year median for Total Debt is $31.7 million (2025), against an average of $25.4 million.
• Across the five-year window, Total Debt soared 3282.91% in 2024 and gained 4.35% in 2026, its largest moves.
• Year by year, Total Debt stood at $629222.0 in 2023, then soared by 3409.73% to $22.1 million in 2024, then jumped by 49.64% to $33.0 million in 2025, then climbed by 0.1% to $33.1 million in 2026.
• Per Business Quant, the three latest TLSI Total Debt figures stand at $33.1 million (Q1 2026), $33.0 million (Q4 2025), and $32.8 million (Q3 2025).